Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)
20 janv. 2022 08h30 HE
|
Compass Therapeutics
BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
HIMALAYA INVESTS IN GENBIO TO PROMOTE GLOBAL WELLNESS; PLANS “FOMO CAN”
13 déc. 2021 06h15 HE
|
Himalaya Technologies, Inc.
Chicago, IL, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Himalaya Technologies, Inc. (OTC: HMLA; “Himalaya”) and GenBio, Inc. (“GenBio”) have agreed to a 19.9% share exchange and a collaboration on a range of...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PolarityTE, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PTE
07 oct. 2021 17h45 HE
|
The Rosen Law Firm PA
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and...
ROSEN, A RESPECTED AND LEADING FIRM, Encourages PolarityTE, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – PTE
29 sept. 2021 16h08 HE
|
The Rosen Law Firm PA
NEW YORK, Sept. 29, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
FDA Approves Phase II Kidney Cancer Therapy Study
13 sept. 2021 18h41 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug...
QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer
25 août 2021 09h00 HE
|
QSAM Biosciences Inc.
Austin, TX, Aug. 25, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam®), for the treatment...
BioStem Technologies, Inc., Announces the Engagement of Biologics Consulting To Support FDA Strategies and Submissions.
27 juil. 2021 09h00 HE
|
BioStem Technologies, Inc.
Pompano Beach, Fl., July 27, 2021 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a pre-clinical-stage biotechnology company focused on harnessing...
Rapid Therapeutic Prepares to file Investigational New Drug Application for its CBD Metered Dose Inhaler with FDA
02 juin 2021 07h00 HE
|
Rapid Therapeutic Science Laboratories
DALLAS, June 02, 2021 (GLOBE NEWSWIRE) -- Rapid Therapeutic Science Laboratories, Inc. (OTC Pink: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing company focused on delivery of...
Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology
17 mars 2021 08h33 HE
|
Bioanalytical Systems, Inc.
WEST LAFAYETTE, Ind., March 17, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Voyager Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline – VYGR
23 févr. 2021 19h45 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...